KAITLYN DIAZ: Open Payments
NPI 1154184943 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,542 in 204 payments from 26 companies in 2025. Trend: 2023 $166 · 2024 $3,504 · 2025 $5,542
Food & beverage: $5,443Education: $99
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 24 | $1,029 |
| Regeneron Healthcare Solutions, Inc. | 12 | $566 |
| GENZYME CORPORATION | 12 | $478 |
| Galderma Laboratories, L.P. | 13 | $451 |
| CSL Behring | 24 | $433 |
| Genentech USA, Inc. | 13 | $365 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $342 |
| Novartis Pharmaceuticals Corporation | 12 | $236 |
| GlaxoSmithKline, LLC. | 17 | $206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $193 |
Products named: DUPIXENT, NEMLUVIO, TEZSPIRE, Xolair, NEFFY, FASENRA, Andembry, AIRSUPRA.
Industry payments across TX — which companies pay providers there.
